Left atrial (LA) function index (LAFI) is a rhythm-independent index that combines LA emptying fraction (LAEF), adjusted LA volume (LAVi), and stroke volume. We evaluated LAFI as a predictor of long-term survival in outpatients with heart failure with reduced ejection fraction (HFrEF).
Introduction
Heart failure (HF) is defined as the inability of the heart to meet the oxygen demand of metabolizing tissues. 1 HF with reduced left ventricular ejection fraction (HFrEF) is primarily defined by a decrease in left ventricular (LV) systolic function, although concomitant diastolic dysfunction is common. The atrial contribution to LV filling is 35%. 2 The early stages of HF show an increased atrial response with increased reservoir and pump function. However, with progression of LV dysfunction, the left atrium (LA) contribution to LV filling gradually decreases. 3, 4 LA volume is a predictor of HF and survival in patients with cardiovascular and cerebrovascular diseases 5 -8 and is a marker of the severity 9,10 and duration 8 of diastolic dysfunction. The LA functional index (LAFI) combines the reservoir function (fractional change), adjusted LA volume (LA volume index), and stroke volume, 11, 12 and thus reflects both LV systolic and diastolic function. In coronary patients with preserved LV function, LAFI was a predictor of cerebral infarction 13 and hospitalization for HF, 14 independent of atrial fibrillation. The calculation of LAFI is also independent of heart rhythm and has a low inter-and intra-observer measurement variation. 15 These characteristics and the simplicity of its calculation make LAFI promising for use in HFrEF patients.
The main objective of the present study was to evaluate LAFI as a predictor of long-term survival in clinically stable and optimally treated outpatients with HFrEF. Secondary objectives included a subgroup analysis of patients with or without atrial fibrillation, and an evaluation of the association of LAFI with patients' clinical characteristics, medical therapy, and N-terminal pro-brain natriuretic peptide (Nt-proBNP).
Methods

Study cohort
A total of 203 consecutive patients were recruited according to the inclusion criteria from a single specialized outpatient HF unit in a university hospital, between May 2010 and October 2013. Patients with HFrEF, according to the European Society of Cardiology guidelines, 1 with LV ejection fraction (LVEF) ,40% by transthoracic echocardiography, were included. Patients were required to have completed the nurse-led HF education programme, achieved optimal HF therapy (according to two cardiologists from the HF unit), and be clinically stable. The study conformed to the principles outlined in the 1964 Declaration of Helsinki. The experimental protocol was approved by the institutional review board, and written consent was obtained from all patients.
Optimal medical treatment was defined as up-titration to either the maximum tolerated dose or a target dose (TD) of angiotensinconverting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), and b-blocker (BB), according to European Society of Cardiology HF guidelines. 1 The agreement of two senior specialists in cardiac insufficiency was required to set therapy as optimized. Clinical stability was defined as no hospital admission or HF decompensation, no change in the New York Heart Association (NYHA) functional class, and no change in the furosemide dosage during a 6-month period.
Follow-up and clinical outcome data
The follow-up time was 3 years, and the outcome was all-cause death.
Patients who did not attend scheduled observation were contacted by telephone to ensure adherence to protocols. The circumstances of the incident were determined from hospital records and/or interviews with relatives. However, we were unable to determine the exact cause of death of some patients because of out-of-hospital death (n ¼ 19). We compared subgroups of patients with an unknown cause of death with those with a known cause of death for clinical, laboratory, and therapeutic profiles. There were no significant differences between the subgroups.
Baseline characteristics
At the baseline visit, several parameters covering clinical, laboratory, electrocardiographic, and echocardiographic domains were entered into a database. The complete list is shown in Supplementary data online, Text S1. Heart rhythm was evaluated by electrocardiogram.
Echocardiography
Echocardiograms were obtained using an echocardiography machine (Vivid 7; GE Healthcare, General Electric, Milwaukee, WI, USA) with an M4S cardiac probe. Images were stored and processed offline in Echopac version 13 (GE Vingmed Ultrasound GE Healthcare, Horten, Norway) by reviewers who were not blinded to the groups (L.S. and S.L.).
LA indexes and LAFI
The LA maximal (LAESVi) and minimal (LAEDVi) indexed volumes were measured and used to calculate the LA emptying fraction (LAEF): 
Parameters of LA function
The mitral inflow was obtained by pulsed Doppler (sweep speed ¼ 100 mm/s) from the apical four-chamber view, and the peak velocities of the early diastole E wave and the late atrial contraction were used to determine the E/A ratio. Two-dimensional strain imaging was used to acquire the peak velocity in early diastole (GSRe) and the active atrial contraction (GSRa).
Other echocardiographic measurements
Several parameters were determined from the resting echocardiograms according to reported guidelines. 16 LV systolic function was characterized by the LVEF and LV global strain (LVGS). For ventricular strain imaging (LVGS, GSRe, and GSRa), three-beat, two-dimensional greyscale, and digital clips of the apical two-, three-, and four-chamber views of the LV (average frame rate ¼ 45 + 11 frames/min) were transferred to Echopac version 13 and processed offline (L.S. and S.L.).
Statistics
Continuous variables are expressed as means + standard deviation or median and interquartile range depending on whether the distribution was normal. For each LAFI quartile, we calculated the death rate per 100 patientyears. Cox regression covariate-adjusted incremental models were used to estimate effects for each covariate, with simultaneous adjustment for potential confounders in multivariable models. Proportional hazards assumptions were verified. Multivariable models were adjusted for significant covariates in the univariate analysis that were clinically relevant. Model 1 included only non-echo parameters: age, body mass index, ischaemic and hypertensive aetiology, atrial fibrillation, ACEi/ARB plus BB, furosemide .40 mg/day, glomerular filtration rate, red cell distribution width, haemoglobin, and logNT-proBNP. Model 2 included the parameters of Model 1 and the parameters that characterized atrial morphology/function (LAESVi, LAEF, mitral peak velocity A wave, and GSRa). Model 3 added LVGS to Model 2. Finally, Model 4 included the NYHA class. A specific sub-analysis was performed according to patients' rhythm (sinus rhythm vs. atrial fibrillation), adjusted for Model 1, because of the high incidence of atrial fibrillation in HFrEF patients. Patients with chronic and paroxysmal atrial fibrillation were included in the atrial fibrillation subgroup. We used c-statistics and x 2 likelihood ratio testing to compare the discrimination of LAFI with each of its components and non-echocardiographic covariates (Model 1). Data were stored and analysed using the statistical package SPSS w 22.0 for Windows (IBM Corp., Armonk, NY, USA).
Results
We described the clinical, demographic, therapeutic, and echocardiographic characteristics of all patients in Tables 1 and 2 . LAFI and demographics, clinical characteristics, medical therapy, and other biomarkers LAFI ( Figure 1 ) and LAFI quartiles ( Tables 1 and 2 ) were associated with severity of HF (NYHA, NT-proBNP), heart rhythm, therapeutics, LVGS, and GSRa. Further, there was a significant correlation of LAFI ( Figure 2 ) with logNT-proBNP, LVGS, GSRa, and the parameters included in the calculation of LAFI.
LAFI and survival
Survivors had higher LAFI values than those in deceased subjects (25.0 + 16.8 vs. 14.5 + 11.8, respectively; P , 0.001). The death rate ( Figure 3 ) increased from 2.4 per 100 person-years in the highest LAFI quartile to 21.7 in the lowest quartile. LAFI and its components had similar receiver operating characteristic (ROC) curves for death ( Figure 4 ). The calculated optimal point of LAFI for death was ≤24.5, with a sensitivity and specificity of 88.5 and 47.9%, respectively. The sensitivity and specificity for LAFI ≤16.57 were 73.8 and 59.7%, respectively. The discrimination of LAFI for death was superior to each of its individual components (unadjusted c-statistics, LAFI 0.7, LVOT-VTI 0.65, LAEF 0.6, and LAESVi 0.66). Further, Cox models showed that LAFI provided a higher prognostic value than did each of its individual components ( patients in quartiles 1 and 2 had a higher risk of death for Models 1-3 ( Table 3 and Figure 5 ). In contrast, using LAFI Q1 (,9.27) as a reference and adjusting for Model 3, quartiles Q2 (HR ¼ 0.24; P ¼ 0.052), Q3 (HR ¼ 0.091; P ¼ 0.015), and Q4 (HR ¼ 0.020; P ¼ 0.006) were associated with improved survival. When NYHA was included (Model 4), increasing LAFI quartiles (HR ¼ 0.35; 95% CI 0.13-0.96; P , 0.001) were associated with increasing survival, but were significant only for the comparison of Q4 with Q1 (HR ¼ 0.018; 95% CI 0.01-0.53; P ¼ 0.020).
LAFI, survival, and heart rhythm
We constituted two subgroups of patients according to heart rhythm (sinus rhythm and atrial fibrillation). LAFI and increasing LAFI quartiles were univariate predictors of survival and remained significant after adjusting for Model 1 ( Table 4) . LAFI .16.57 (HR ¼ 0.22, 95% CI 0.08 -0.6; P ¼ 0.003) was the only significant predictor of survival in the sinus rhythm subgroup.
Discussion
The present study provides novel evidence that LAFI is a predictor of long-term survival in stable outpatients with HFrEF. Importantly, the prognostic value was independent of a wide range of clinical, LAFI and systolic HF survival laboratory, therapeutic, and echocardiographic covariates and was heart rhythm independent.
Left atrial functional index
Because of the individual components used in the LAFI calculation formula, 15 which associate LA function and morphology with LV systolic function, LAFI is dependent on LA reservoir function and is adjusted for cardiac output and indexed atrial volume. All these parameters are rhythm independent. Thus, LAFI can be calculated in patients with chronic and paroxysmal fibrillation and in those receiving ablation for atrial fibrillation. 12, 13, 17 Atrial fibrillation is a frequent co-morbidity in HFrEF and is a predictor of mortality. Indeed, in the present study, almost one-third of patients had atrial fibrillation. By definition, all HFrEF patients have decreased LVEF, but may not exhibit LA dysfunction, which can influence prognosis. A patient with low cardiac output, but normal LA volume and function, will likely have a different prognosis than a patient with LA enlargement and LA systolic dysfunction. Thus, the combination of LV systolic and diastolic functions in one index may provide additional prognostic information.
Numerous new markers and multi-panel algorithms for risk stratification are constantly being assessed, although they are often not translated to clinical practice or do not provide information on the physiopathological processes. Further, some methods are based on advanced echocardiography that requires time-consuming postprocessing. In contrast, LAFI is easily calculated from three echocardiographic parameters obtained with standard echocardiography without post-processing or advanced calculations.
In the present study, patients were recruited only after finishing the educational programme, achieving optimal therapy, and after 6 months of clinical stability to avoid the positive effects of drug titration on ventricular remodelling.
LAFI and HF severity
Previous studies have evaluated LAFI only in patients with preserved systolic function. 12, 13, 17 In contrast, we included only outpatients with HFrEF. Although LAFI is an echocardiographic index, it was CI, confidence interval; HR, hazard ratio; Q1, Q2, Q3, and Q4, LAFI quartiles; Amt, late transmitral flow velocity; LAEF, left atrial emptying fraction; LAVi, left atrial indexed volume; sPAP, peak systolic pulmonary artery pressure; LVGS, left ventricle global strain; GSRa, strain rate of the mitral A peak; ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin type 1 receptor blockers; BB, b-blockers; logNT-proBNP, log amino-terminal pro-brain natriuretic peptide. a Model 1: Adjusted for age, glomerular filtration rate, ischaemic and hypertensive aetiologies, atrial fibrillation, ACEi/ARB + BB therapy, furosemide .40 mg/day, body mass index, red cell distribution width, haemoglobin, and logNT-proBNP. associated with clinical severity (NYHA), co-morbidities (diabetes, ischaemic aetiology), age, renal function, NT-proBNP, and LV systolic (LVGS) and diastolic (GSRa) function. Patients in the lower LAFI quartile had more severe HF, and worse renal function, LV systolic function, and other biomarkers. Thus, the prognostic value of LAFI may reflect only the effect of these risk factors. To reduce potential confounder effects, the survival models were incremental and were adjusted for all significant confounders. This multidimensional aspect of LAFI may explain the association of LAFI quartiles with survival despite the similar LVEF values throughout the quartiles. Nevertheless, LV systolic function was also characterized by LVGS, which more closely reflects the active component of ventricular function, 18 and was included in the survival models.
LAFI and survival
We also found that LAFI was a strong predictor of survival, with a higher prognostic value than the various associated risk factors. As there were no prior studies of LAFI in HFrEF, we categorized LAFI according to quartiles, as in previous studies with LAFI, 14, 15 allowing us to compare between studies. This 'non-outcome-based method' of dichotomization reduces bias and improves reproducibility. 19 The ROC curve for death was associated with LAFI and showed good sensitivity with low specificity, while LAFI ,16.57 had slightly better specificity, but was still low. Thus, a negative test (high LAFI value) suggests that outcome (death) is most likely (low false-negative), while a positive test (low LAFI) is not particularly helpful because of the high false-positive rate. Although this analysis has not been reported previously, 14 our data suggest that LAFI may help identify subgroups of patients at lower risk of death. This is important, as once the educational programme and therapy optimization in the HF clinic is complete, lower-risk patients should be referred for follow-up with a general practitioner. LAFI quartiles and LAFI ≥16.57 were predictors of survival in all tested survival models. We used incremental models to evaluate LAFI as a survival predictor, after adjustment for a wide range of clinical parameters, biomarkers, optimal therapy, rhythm, LV systolic function, and echocardiographic parameters that characterized LA morphology and function and LV systolic function. LAFI discrimination value to death was higher than that of its components and added significant prognostic value to Model 1, which includes only non-echocardiographic parameters. These results were similar to previous study. 14 The first quartile defined a high-risk subgroup compared with all other quartiles. In contrast, there were no differences in the upper two quartiles between patients, suggesting that patients with LAFI above the median (16.57) were at lower risk of death. Previously, only the comparison between the lower and upper quartiles was found to be significant. 14 Atrial fibrillation was included in all tested models. However, subgroup analysis according to rhythm (sinus rhythm vs. atrial fibrillation) showed that LAFI remained a significant predictor of survival in both subgroups and after adjustment for Model 1.
Clinical implications
Previous studies have reported that LAFI was an independent predictor of HF and stroke in patients with preserved LV systolic function. The present study showed that LAFI is also a strong and independent predictor of long-term survival in stable outpatients with HFrEF. LAFI is an echocardiographic parameter that is rapidly and easily calculated from three classical and standardized parameters that are readily available in all patients with HFrEF. Finally, heart rhythm is not a limiting factor for LAFI calculation and data interpretation, which is important in HFrEF as almost a third of patients have atrial fibrillation.
Study limitations
There are several potential limitations to our study. This was a single-centre study with a small sample size. This limits the generalizability of our findings but allows better control and compliance with the study protocol, as evidenced by the absence of dropout cases in follow-up. The clinical routine recruitment may also influence accuracy, which is less than that in prospective studies, although this reflects a true clinical cohort of HF patients. Further, the team was fully aware of the echocardiogram results. However, blinding was impossible, as the HF unit medical staff were also responsible for echocardiogram testing. Finally, the time to achieve optimal medical therapy was not analysed and may have differed from patient to patient. However, our goal was to investigate only patients the HF unit team considered as having achieved optimal therapy according to current guidelines. Further studies are required to validate the use of LAFI in HFrEF.
Conclusion
LAFI is a strong and independent predictor of long-term survival in stable outpatients with HFrEF. LAFI provided incremental prognostic value over clinical risk factors, heart rhythm, NT-proBNP, and echocardiographic covariates. These findings emphasize the importance of assessing LA function in patients with HFrEF.
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Supplementary data are available at European Journal of Echocardiography online.
